MACUGEN Drug Patent Profile
✉ Email this page to a colleague
When do Macugen patents expire, and when can generic versions of Macugen launch?
Macugen is a drug marketed by Bausch And Lomb Inc and is included in one NDA.
The generic ingredient in MACUGEN is pegaptanib sodium. Additional details are available on the pegaptanib sodium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MACUGEN?
- What are the global sales for MACUGEN?
- What is Average Wholesale Price for MACUGEN?
Summary for MACUGEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 44 |
| Drug Prices: | Drug price information for MACUGEN |
| DailyMed Link: | MACUGEN at DailyMed |
Recent Clinical Trials for MACUGEN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Oslo University Hospital | Phase 4 |
| Retina Vitreous Associates of Florida | N/A |
| Vision Research Foundation | Phase 2 |
US Patents and Regulatory Information for MACUGEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MACUGEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MACUGEN
See the table below for patents covering MACUGEN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 0832299 | UTILISATION DE LIGANDS D'ACIDE NUCLEIQUE EN CYTOMETRIE DE FLUX (USE OF NUCLEIC ACID LIGANDS IN FLOW CYTOMETRY) | ⤷ Sign Up |
| Australia | 2601697 | ⤷ Sign Up | |
| European Patent Office | 0888374 | ACIDES NUCLEIQUES LIGANDS A FORTE AFFINITE POUR LA PROTEINE C1q DU SYSTEME COMPLEMENTAIRE (HIGH AFFINITY NUCLEIC ACID LIGANDS OF THE COMPLEMENT SYSTEM PROTEIN C1q) | ⤷ Sign Up |
| Germany | 69739880 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MACUGEN
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0957929 | 20/2006 | Austria | ⤷ Sign Up | PRODUCT NAME: PEGAPTANIB UND SALZE DAVON; REGISTRATION NO/DATE: EU/1/05/325/001 20060131 |
| 0957929 | CA 2006 00021 | Denmark | ⤷ Sign Up | PRODUCT NAME: PEGAPTANIB, NATRIUM |
| 0957929 | 132006901428637 | Italy | ⤷ Sign Up | PRODUCT NAME: PEGAPTANIB SODICO(MACUGEN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/05/325/001, 20060131 |
| 0957929 | SZ 20/2006 | Austria | ⤷ Sign Up | PRODUCT NAME: PEGAPTANIB UND SALZE DAVON |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
